Parkinsoism Produced by an Endogenous Substance, Tetrahydroisoquinoline, in Monkeys and Mice

  • Mitsuo Yoshida
  • Matsuo Ogawa
  • Toshimitsu Niwa
  • Toshiharu Nagatsu
Part of the Advances in Behavioral Biology book series (ABBI, volume 38A)


The discovery by Langston et al1. that 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP), a side product of meperidine, produced symptoms quite similar to those of Parkinson’s disease in humans promoted research toward elucidation of the etiology of Parkinson’s disease. MPTP, however, can not be a causal substance to produce Parkinson’s disease, since MPTP does not exist in the natural environment. Barbeau et al2. suggested that paraquat, a herbicide having a similar chemical structure to MPTP, might cause Parkinson’s disease, since a high incidence of the disease was observed in an agricultural area where paraquat was used compared with that in other areas they surveyed. This suggestion, however, can not be true, as the disease had already been described 1817 by James Parkinson when such an industry product did not exist.


Substantia Nigra Similar Chemical Structure Levodopa Administration Tyrosine Hydroxylase Activity Nigrostriatal Neuron 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J. W. Langston, P. Ballard, J. W. Tetrud, and I. Irwin, Chronic parkinsonism in humans due to a product of meperidine-analog synthesis, Science 219: 979 (1983).PubMedCrossRefGoogle Scholar
  2. 2.
    A. Barbeau, T. Cloutier, M. Roy, L. Plasse, S. Paris, and J. Poirier, Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine, Lancet 11: 1213 (1985).CrossRefGoogle Scholar
  3. 3.
    T. Nagatsu and Y. Hirata, Inhibition of the tyrosine hydroxylase system by MPTP,1-methyl-4-phenylpyridinium ion (MPP+) and the structurally related compounds in vitro and in vivo, Europ. Neurol. 26 Suppl. 1: 11 (1987).PubMedCrossRefGoogle Scholar
  4. 4.
    M. Kohno, S. Ohta, and M. Hirobe, Tetrahydroisoquinoline and 1methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain, Biochem. Biophys. Res. Commun. 140: 448 (1986).PubMedCrossRefGoogle Scholar
  5. 5.
    S. Ohta, M. Kohno, Y. Makin, O. Tachikawa, and M. Hirobe, Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline are present in the human brain: Relation to parkinson’s disease, Biomed. Res. 8: 453 (1987).Google Scholar
  6. 6.
    T. Niwa, N. Takeda, N. Kaneda, Y. Hashizume, and T. Nagatsu, Presence of tetrahydroisoquinoline and 2-methyl-tetrahydro-isoquinoline in parkinsonian and normal human brains, Biochem. Biophys. Res. Commun. 144: 1084 (1987).PubMedCrossRefGoogle Scholar
  7. 7.
    Y. Makin, S. Ohta, O. Tachikawa, and M. Hirobe, Presence of tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline in foods: Compounds related to Parkinson’s disease, Life Sci. 43: 373 (1988).CrossRefGoogle Scholar
  8. 8.
    T. Niwa, H. Yoshizumi, A. Tatematsu, S. Matsuura, and T. Nagatsu, Presence of tetrahydroisoquinoline, a parkinsonismrelated compound, in foods, J. Chromatog. 493: 347 (1989).CrossRefGoogle Scholar
  9. 9.
    T. Nagatsu, and M. Yoshida, An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions, Neurosci. Lett. 87: 178 (1988).PubMedCrossRefGoogle Scholar
  10. 10.
    K. Oka, G. Ashiba, T. Sugimoto, S. Matsuura, and T. Nagatsu, Kinetic properties of tyrosine hydroxylase purified from bovine adrenal medulla and bovine caudate nucleus, Biochim. Biophys. Acta 706: 188 (1982).PubMedCrossRefGoogle Scholar
  11. 11.
    T. Fukushima, and J. C. Nixon, Analysis of reduced forms of biopterin in biological tissues and fluids. Anal. Biochem. 102: 176 (1980).PubMedCrossRefGoogle Scholar
  12. 12.
    T. Nagatsu, K. Oka, and T. Kato, Highly sensitive assay for tyrosine hydroxylase activity by high performance liquid chromatography, J. Chromatogr. 163: 247 (1979).PubMedCrossRefGoogle Scholar
  13. 13.
    M. Ogawa, M. Araki, I. Nagatsu, T. Nagatsu, and M. Yoshida, The effect of 1,2,3,4-tetrahydroisoquinoline (TIQ) on mesencephalic dopaminergic neurons in C57BL/6J mice: Immunohistochemical studies-tyrosine hydroxylase, Biogenic Amines 6: 427 (1989).Google Scholar
  14. 14.
    I. Nagatsu, Immunohistochemistry of biogenic amines and immunoenzyme-histocytochemistry on catecholamine-synthesizing enzymes: Application for axoplasmic transport and neuronal localization, in: Methods of Biogenic Amine Res. Elsevier, Amsterdam, 873 (1983).Google Scholar
  15. 15.
    G. A. Ricaurte, J. W. Langston, L. E. Delanney, I. Irwin, S. J. Peroutka, and L. S. Forno, Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine: a neurochemical and morphological reassessment, Brain Res. 376: 117 (1986).PubMedCrossRefGoogle Scholar
  16. 16.
    T. Saitoh, K. Niijima, and Y. Mizuno, Long-term effect of 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine content in young and mature mice, J. Neurol. Sci. 77: 229 (1987).PubMedCrossRefGoogle Scholar
  17. 17.
    S. Mori, J. Fujitake, S. Kuno, and Y. Sano, Immunohistochemical evaluation of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) on dopaminergic nigrostriatal neurons of young adult mice using dopamine and tyrosine hydroxylase antibodies, Neurosci. Lett. 90: 57 (1988).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Mitsuo Yoshida
    • 1
  • Matsuo Ogawa
    • 1
  • Toshimitsu Niwa
    • 2
  • Toshiharu Nagatsu
    • 3
  1. 1.Dept. of NeurologyJichi Medical SchoolTochigikenJapan
  2. 2.Dept. Internal MedicineNagoya University Branch HospitalJapan
  3. 3.Dept. BiochemistryNagoya UniversityNagoyaJapan

Personalised recommendations